HK1213559A1 - 作為 受體激動劑的吡咯並 嘧啶衍生物 - Google Patents

作為 受體激動劑的吡咯並 嘧啶衍生物

Info

Publication number
HK1213559A1
HK1213559A1 HK16101493.2A HK16101493A HK1213559A1 HK 1213559 A1 HK1213559 A1 HK 1213559A1 HK 16101493 A HK16101493 A HK 16101493A HK 1213559 A1 HK1213559 A1 HK 1213559A1
Authority
HK
Hong Kong
Prior art keywords
pyrrolo
receptor agonists
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
HK16101493.2A
Other languages
English (en)
Inventor
尢偉．格雷瑟
金原篤
馬蒂亞斯．內特科文
斯蒂芬．勒韋爾
馬克．羅杰斯-埃文斯
坦賈．舒爾茲-加施
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1213559A1 publication Critical patent/HK1213559A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
HK16101493.2A 2013-05-02 2016-02-11 作為 受體激動劑的吡咯並 嘧啶衍生物 HK1213559A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (1)

Publication Number Publication Date
HK1213559A1 true HK1213559A1 (zh) 2016-07-08

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101493.2A HK1213559A1 (zh) 2013-05-02 2016-02-11 作為 受體激動劑的吡咯並 嘧啶衍生物

Country Status (35)

Country Link
US (1) US9580435B2 (zh)
EP (1) EP2991988B1 (zh)
JP (1) JP6454689B2 (zh)
KR (1) KR20160002857A (zh)
CN (1) CN105164133B (zh)
AR (1) AR096153A1 (zh)
AU (1) AU2014261546B2 (zh)
BR (1) BR112015027394A8 (zh)
CA (1) CA2907691A1 (zh)
CL (1) CL2015003196A1 (zh)
CR (1) CR20150555A (zh)
CY (1) CY1119114T1 (zh)
DK (1) DK2991988T3 (zh)
EA (1) EA028123B1 (zh)
ES (1) ES2635632T3 (zh)
HK (1) HK1213559A1 (zh)
HR (1) HRP20171099T1 (zh)
HU (1) HUE035333T2 (zh)
IL (1) IL242162B (zh)
LT (1) LT2991988T (zh)
MA (1) MA38555B1 (zh)
MX (1) MX2015014081A (zh)
MY (1) MY182237A (zh)
NZ (1) NZ712030A (zh)
PE (1) PE20160039A1 (zh)
PH (1) PH12015502409A1 (zh)
PL (1) PL2991988T3 (zh)
PT (1) PT2991988T (zh)
RS (1) RS56313B1 (zh)
SG (1) SG11201509029PA (zh)
SI (1) SI2991988T1 (zh)
TW (1) TWI680129B (zh)
UA (1) UA116801C2 (zh)
WO (1) WO2014177527A1 (zh)
ZA (1) ZA201507008B (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116395C2 (uk) 2013-09-06 2018-03-12 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ ТРИАЗОЛ[4,5-b]ПІРИМІДИНУ
PE20170683A1 (es) * 2014-11-07 2017-05-22 Hoffmann La Roche Triazolo[4,5-d]pirimidinas como agonistas del receptor canabinoide 2
EP3475280B1 (en) 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
KR20230062680A (ko) 2016-06-23 2023-05-09 에프. 호프만-라 로슈 아게 2형 칸나비노이드 수용체에 대한 친화성을 갖는 [1,2,3]트라이아졸로[4,5-d]피리미딘 유도체
JP6964099B2 (ja) 2016-06-23 2021-11-10 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 新規［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン誘導体
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
US7271266B2 (en) 2002-03-28 2007-09-18 Merck & Co., Inc. Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
TWI270549B (en) * 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
CN101454327A (zh) * 2006-03-30 2009-06-10 Irm责任有限公司 作为大麻素1活性抑制剂的吡咯并嘧啶类化合物
US20110206607A1 (en) * 2007-05-10 2011-08-25 Roger Olsson Imidazol (1,2-a)pyridines and related compounds with activity at cannabinoid cb2 receptors
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
US20100227845A1 (en) 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
JP5629324B2 (ja) * 2009-10-15 2014-11-19 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
CA2876443A1 (en) 2012-07-04 2014-01-09 F. Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
US9409866B2 (en) 2012-12-07 2016-08-09 Hoffmann-La Roche Inc. Pyridine-2-amides useful as CB2 agonists
EA025841B1 (ru) 2012-12-07 2017-02-28 Ф. Хоффманн-Ля Рош Аг Пиридин-2-амиды, пригодные в качестве агонистов каннабиноидного рецептора 2
SG11201504011UA (en) 2012-12-07 2015-07-30 Hoffmann La Roche Novel pyrazine derivatives as cb2 receptor agonists
JP6426618B2 (ja) 2012-12-07 2018-11-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 新規なピリジン誘導体
SI2964646T1 (sl) 2013-03-07 2017-08-31 F. Hoffmann-La Roche Ag Novi derivati pirazola
EP2991987B1 (en) 2013-05-02 2018-05-23 F.Hoffmann-La Roche Ag Purine derivatives as cb2 receptor agonists

Also Published As

Publication number Publication date
PT2991988T (pt) 2017-07-25
SG11201509029PA (en) 2015-12-30
RS56313B1 (sr) 2017-12-29
PE20160039A1 (es) 2016-01-28
AU2014261546B2 (en) 2018-01-18
HRP20171099T1 (hr) 2017-10-06
PH12015502409B1 (en) 2016-02-22
LT2991988T (lt) 2017-08-10
CN105164133A (zh) 2015-12-16
ZA201507008B (en) 2017-08-30
JP6454689B2 (ja) 2019-01-16
SI2991988T1 (sl) 2017-09-29
TWI680129B (zh) 2019-12-21
CY1119114T1 (el) 2018-02-14
HUE035333T2 (en) 2018-05-02
CR20150555A (es) 2015-11-20
PH12015502409A1 (en) 2016-02-22
CA2907691A1 (en) 2014-11-06
US20160046637A1 (en) 2016-02-18
NZ712030A (en) 2021-03-26
MY182237A (en) 2021-01-18
US9580435B2 (en) 2017-02-28
MX2015014081A (es) 2015-12-11
EA028123B1 (ru) 2017-10-31
CN105164133B (zh) 2018-02-13
DK2991988T3 (en) 2017-08-21
MA38555A1 (fr) 2017-09-29
MA38555B1 (fr) 2018-04-30
IL242162B (en) 2019-06-30
KR20160002857A (ko) 2016-01-08
BR112015027394A8 (pt) 2018-01-30
EP2991988B1 (en) 2017-05-31
AR096153A1 (es) 2015-12-09
JP2016517874A (ja) 2016-06-20
TW201522343A (zh) 2015-06-16
EP2991988A1 (en) 2016-03-09
PL2991988T3 (pl) 2017-10-31
ES2635632T3 (es) 2017-10-04
BR112015027394A2 (pt) 2017-07-25
UA116801C2 (uk) 2018-05-10
AU2014261546A1 (en) 2015-09-24
CL2015003196A1 (es) 2016-06-03
WO2014177527A1 (en) 2014-11-06
EA201591939A1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
HRP20190361T1 (hr) Derivati triazolo[4,5-d]pirimidina kao antagonisti cb2 receptora
ZA201506570B (en) 2-phenylimidazo[1,2-a]pyrimidines as imaging agents
HK1213559A1 (zh) 作為 受體激動劑的吡咯並 嘧啶衍生物
SG11201402197UA (en) [1, 2, 3] triazolo [4, 5 -d] pyrimidine derivatives as agonists of the cannabinoid receptor 2
HRP20181141T1 (hr) Derivati purina kao agonisti cb2 receptora
IL232304A0 (en) [1,2,3]-Triazolo[4,5-d]pyrimidine derivatives are agonistic for cannabinoid receptor 2 agonists
LT2928882T (lt) Pirazino dariniai kaip cb2 receptoriaus agonistai